Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
24 hedge funds and large institutions have $3.48M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.
2% less capital invested
Capital invested by funds: $3.56M → $3.48M (-$73.3K)
8% less funds holding
Funds holding: 26 → 24 (-2)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$4.59K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$128 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$223K |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$25K |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
-$14.2K |
| 4 |
CAC
Cowen and Company
New York
|
-$1.88K |
| 5 |
AGM
Alpine Global Management
New York
|
-$1.57K |
CLDI.WS Hedge Fund Activity: Q4 2022 in Review
24 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q4 2022, worth a combined $3.48M — down 2.1% from $3.56M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CLDI.WS and 0 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was Periscope Capital, adding an estimated $4.59K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $223K sold.
- 24 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q4 2022, down from 26 in Q3 2022.
- Funds reported $3.48M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q4 2022, down 2.1% quarter-over-quarter.
- 0 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q4 2022 and 2 closed out, a net change of -2 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q4 2022 was Periscope Capital, an estimated $4.59K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q4 2022 was Boothbay Fund Management, an estimated $223K sold.
Based on aggregated 13F filings for Q4 2022.